logo-loader

Medicus Pharma marks one-year Nasdaq anniversary, advances Phase 2 therapeutics

Published: 10:09 20 Jan 2026 EST

Medicus Pharma -

Medicus Pharma (NASDAQ:MDCX) will ring the Nasdaq Opening Bell on January 22, marking its one-year Nasdaq anniversary.

The biotech company focuses on advancing novel therapeutics, including SkinJect for basal cell carcinoma ($2 billion market) and Teverelix for advanced prostate cancer ($6 billion market).

Since listing, Medicus has progressed Phase 2 programs and pursued strategic partnerships for late-stage development.

CEO Dr. Raza Bokhari highlighted the company’s focus on execution and shareholder support.

“Our emphasis since becoming a public company has been on execution,” the CEO told investors in a statement.

“We are advancing a focused portfolio of therapies, anchored by our Skinject Phase 2 program, which is approaching database lock and clinical data readout resulting in potential partnering opportunity. We very much value the continued support of our shareholders in assembling decision-grade clinical and regulatory packages in therapeutic indications with significant unmet medical needs.”

Medicus Pharma shares rationale as CD228V becomes lead development priority

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug...

1 week, 2 days ago